Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

[Image: see text] Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competiti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Deng, Xianming, Okram, Barun, Ding, Qiang, Zhang, Jianming, Choi, Yongmun, Adrián, Francisco J., Wojciechowski, Amy, Zhang, Guobao, Che, Jianwei, Bursulaya, Badry, Cowan-Jacob, Sandra W., Rummel, Gabriele, Sim, Taebo, Gray, Nathanael S.
Formato: Artigo
Idioma:Inglês
Publicado: American Chemical Society 2010
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2951064/
https://ncbi.nlm.nih.gov/pubmed/20828158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm100555f
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares